{
  "study_id": "NCT01740427",
  "study_title": "Palbociclib and Letrozole in Advanced Breast Cancer",
  "table_name": "Table 1",
  "table_title": "Patient Demographic and Clinical Characteristics.",
  "description": "Baseline demographic and clinical characteristics of patients in the PALOMA-2 study.",
  "footnotes": [
    "* There were no significant differences in baseline characteristics between the two treatment groups except for Eastern Cooperative Oncology Group (ECOG) performance status (P=0.004). Some percentages do not sum to 100 because of rounding.",
    "† Race was self-reported.",
    "‡ ECOG performance status is measured on a 5-point scale, with 0 indicating no symptoms and higher numbers indicating increasing disability.",
    "§ \"Other\" was an option for the site to select on the clinical report form if none of the other available options were applicable; \"data missing\" means that the site did not complete that field because the information was not available.",
    "¶ Disease-free interval was defined as the time from adjuvant or neoadjuvant therapy to recurrence. Newly metastatic disease (referred to as \"de novo metastatic\" in the protocol) applies to patients who had not received any prior systemic therapy, for whom a determination of disease-free interval was not possible.",
    "|| Patients who received anastrozole or letrozole as a component of their adjuvant or neoadjuvant therapy were excluded from the study if they had disease progression while receiving the therapy or within 12 months after completing the therapy."
  ],
  "groups": [
    {
      "name": "Palbociclib-Letrozole",
      "n": 444,
      "type": "Intervention"
    },
    {
      "name": "Placebo-Letrozole",
      "n": 222,
      "type": "Control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age",
      "standardized_name": "Age",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Median (range) — yr",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "iqr_min": 30.0,
          "iqr_max": 89.0,
          "raw_string": "62 (30-89)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "numeric_median_iqr",
          "median": 61.0,
          "iqr_min": 28.0,
          "iqr_max": 88.0,
          "raw_string": "61 (28-88)"
        }
      ]
    },
    {
      "original_label": "<65 yr — no. (%)",
      "standardized_name": "Age <65 years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 263.0,
          "percentage": 59.2,
          "raw_string": "263 (59.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 141.0,
          "percentage": 63.5,
          "raw_string": "141 (63.5)"
        }
      ]
    },
    {
      "original_label": "≥65 yr — no. (%)",
      "standardized_name": "Age >=65 years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 181.0,
          "percentage": 40.8,
          "raw_string": "181 (40.8)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 81.0,
          "percentage": 36.5,
          "raw_string": "81 (36.5)"
        }
      ]
    },
    {
      "original_label": "Race — no. (%)†",
      "standardized_name": "Race",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "White",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 344.0,
          "percentage": 77.5,
          "raw_string": "344 (77.5)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 172.0,
          "percentage": 77.5,
          "raw_string": "172 (77.5)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Asian",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 14.6,
          "raw_string": "65 (14.6)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 13.5,
          "raw_string": "30 (13.5)"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Black or African American",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 1.8,
          "raw_string": "8 (1.8)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.4,
          "raw_string": "3 (1.4)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 6.1,
          "raw_string": "27 (6.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 7.7,
          "raw_string": "17 (7.7)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status — no. (%)‡",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P-value",
        "statistic_value": 0.004,
        "p_value": 0.004,
        "raw_string": "P=0.004"
      }
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG 0",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 257.0,
          "percentage": 57.9,
          "raw_string": "257 (57.9)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 45.9,
          "raw_string": "102 (45.9)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG 1",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 178.0,
          "percentage": 40.1,
          "raw_string": "178 (40.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 52.7,
          "raw_string": "117 (52.7)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG 2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 2.0,
          "raw_string": "9 (2.0)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.4,
          "raw_string": "3 (1.4)"
        }
      ]
    },
    {
      "original_label": "Disease stage at initial diagnosis — no. (%)",
      "standardized_name": "Disease Stage at Initial Diagnosis",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "I",
      "standardized_name": "Stage I",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage at Initial Diagnosis",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 11.5,
          "raw_string": "51 (11.5)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 13.5,
          "raw_string": "30 (13.5)"
        }
      ]
    },
    {
      "original_label": "II",
      "standardized_name": "Stage II",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage at Initial Diagnosis",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 137.0,
          "percentage": 30.9,
          "raw_string": "137 (30.9)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 68.0,
          "percentage": 30.6,
          "raw_string": "68 (30.6)"
        }
      ]
    },
    {
      "original_label": "III",
      "standardized_name": "Stage III",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage at Initial Diagnosis",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 16.2,
          "raw_string": "72 (16.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 17.6,
          "raw_string": "39 (17.6)"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Stage IV",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage at Initial Diagnosis",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 138.0,
          "percentage": 31.1,
          "raw_string": "138 (31.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 32.4,
          "raw_string": "72 (32.4)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "Unknown",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage at Initial Diagnosis",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 8.1,
          "raw_string": "36 (8.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 5.4,
          "raw_string": "12 (5.4)"
        }
      ]
    },
    {
      "original_label": "Other or data missing§",
      "standardized_name": "Other or Missing Data",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage at Initial Diagnosis",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 2.3,
          "raw_string": "10 (2.3)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.5,
          "raw_string": "1 (0.5)"
        }
      ]
    },
    {
      "original_label": "Recurrence type — no. (%)",
      "standardized_name": "Recurrence Type",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Locoregional",
      "standardized_name": "Locoregional",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Recurrence Type",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.5,
          "raw_string": "2 (0.5)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.9,
          "raw_string": "2 (0.9)"
        }
      ]
    },
    {
      "original_label": "Local",
      "standardized_name": "Local",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Recurrence Type",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.4,
          "raw_string": "6 (1.4)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.4,
          "raw_string": "3 (1.4)"
        }
      ]
    },
    {
      "original_label": "Regional",
      "standardized_name": "Regional",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Recurrence Type",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.7,
          "raw_string": "3 (0.7)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.5,
          "raw_string": "1 (0.5)"
        }
      ]
    },
    {
      "original_label": "Distant",
      "standardized_name": "Distant",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Recurrence Type",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 294.0,
          "percentage": 66.2,
          "raw_string": "294 (66.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 145.0,
          "percentage": 65.3,
          "raw_string": "145 (65.3)"
        }
      ]
    },
    {
      "original_label": "Newly diagnosed",
      "standardized_name": "Newly Diagnosed",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Recurrence Type",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 139.0,
          "percentage": 31.3,
          "raw_string": "139 (31.3)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 71.0,
          "percentage": 32.0,
          "raw_string": "71 (32.0)"
        }
      ]
    },
    {
      "original_label": "Disease-free interval — no. (%)¶",
      "standardized_name": "Disease-Free Interval",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Newly metastatic disease",
      "standardized_name": "Newly Metastatic Disease",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 167.0,
          "percentage": 37.6,
          "raw_string": "167 (37.6)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 81.0,
          "percentage": 36.5,
          "raw_string": "81 (36.5)"
        }
      ]
    },
    {
      "original_label": "≤12 mo",
      "standardized_name": "<=12 months",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 99.0,
          "percentage": 22.3,
          "raw_string": "99 (22.3)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 48.0,
          "percentage": 21.6,
          "raw_string": "48 (21.6)"
        }
      ]
    },
    {
      "original_label": ">12 mo",
      "standardized_name": ">12 months",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 178.0,
          "percentage": 40.1,
          "raw_string": "178 (40.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 93.0,
          "percentage": 41.9,
          "raw_string": "93 (41.9)"
        }
      ]
    },
    {
      "original_label": "Disease site — no. (%)",
      "standardized_name": "Disease Site",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Visceral",
      "standardized_name": "Visceral",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Site",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 214.0,
          "percentage": 48.2,
          "raw_string": "214 (48.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 110.0,
          "percentage": 49.5,
          "raw_string": "110 (49.5)"
        }
      ]
    },
    {
      "original_label": "Nonvisceral",
      "standardized_name": "Nonvisceral",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Site",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 230.0,
          "percentage": 51.8,
          "raw_string": "230 (51.8)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 112.0,
          "percentage": 50.5,
          "raw_string": "112 (50.5)"
        }
      ]
    },
    {
      "original_label": "Bone only",
      "standardized_name": "Bone Only",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Nonvisceral",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 103.0,
          "percentage": 23.2,
          "raw_string": "103 (23.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 48.0,
          "percentage": 21.6,
          "raw_string": "48 (21.6)"
        }
      ]
    },
    {
      "original_label": "No. of disease sites — no. (%)",
      "standardized_name": "Number of Disease Sites",
      "category": "Clinical Characteristics",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "1",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Disease Sites",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 138.0,
          "percentage": 31.1,
          "raw_string": "138 (31.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 29.7,
          "raw_string": "66 (29.7)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "2",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Disease Sites",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 26.4,
          "raw_string": "117 (26.4)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 52.0,
          "percentage": 23.4,
          "raw_string": "52 (23.4)"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "3",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Disease Sites",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 112.0,
          "percentage": 25.2,
          "raw_string": "112 (25.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 27.5,
          "raw_string": "61 (27.5)"
        }
      ]
    },
    {
      "original_label": "≥4",
      "standardized_name": ">=4",
      "category": "Clinical Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Disease Sites",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 77.0,
          "percentage": 17.3,
          "raw_string": "77 (17.3)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 43.0,
          "percentage": 19.4,
          "raw_string": "43 (19.4)"
        }
      ]
    },
    {
      "original_label": "Prior adjuvant or neoadjuvant therapies — no. (%)",
      "standardized_name": "Prior Adjuvant or Neoadjuvant Therapies",
      "category": "Prior Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Chemotherapy",
      "standardized_name": "Prior Chemotherapy",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant or Neoadjuvant Therapies",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 213.0,
          "percentage": 48.0,
          "raw_string": "213 (48.0)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 109.0,
          "percentage": 49.1,
          "raw_string": "109 (49.1)"
        }
      ]
    },
    {
      "original_label": "Neoadjuvant",
      "standardized_name": "Neoadjuvant",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Chemotherapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 12.2,
          "raw_string": "54 (12.2)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 32.0,
          "percentage": 14.4,
          "raw_string": "32 (14.4)"
        }
      ]
    },
    {
      "original_label": "Adjuvant",
      "standardized_name": "Adjuvant",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Chemotherapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 180.0,
          "percentage": 40.5,
          "raw_string": "180 (40.5)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 89.0,
          "percentage": 40.1,
          "raw_string": "89 (40.1)"
        }
      ]
    },
    {
      "original_label": "Adjuvant hormonal therapy||",
      "standardized_name": "Prior Adjuvant Hormonal Therapy",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant or Neoadjuvant Therapies",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 249.0,
          "percentage": 56.1,
          "raw_string": "249 (56.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 126.0,
          "percentage": 56.8,
          "raw_string": "126 (56.8)"
        }
      ]
    },
    {
      "original_label": "Tamoxifen",
      "standardized_name": "Tamoxifen",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 209.0,
          "percentage": 47.1,
          "raw_string": "209 (47.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 98.0,
          "percentage": 44.1,
          "raw_string": "98 (44.1)"
        }
      ]
    },
    {
      "original_label": "Anastrozole",
      "standardized_name": "Anastrozole",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 12.6,
          "raw_string": "56 (12.6)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 13.1,
          "raw_string": "29 (13.1)"
        }
      ]
    },
    {
      "original_label": "Letrozole",
      "standardized_name": "Letrozole",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 8.1,
          "raw_string": "36 (8.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 7.2,
          "raw_string": "16 (7.2)"
        }
      ]
    },
    {
      "original_label": "Exemestane",
      "standardized_name": "Exemestane",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 6.8,
          "raw_string": "30 (6.8)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 5.9,
          "raw_string": "13 (5.9)"
        }
      ]
    },
    {
      "original_label": "Goserelin",
      "standardized_name": "Goserelin",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.1,
          "raw_string": "5 (1.1)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 2.7,
          "raw_string": "6 (2.7)"
        }
      ]
    },
    {
      "original_label": "Toremifene",
      "standardized_name": "Toremifene",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 1.6,
          "raw_string": "7 (1.6)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.5,
          "raw_string": "1 (0.5)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other",
      "category": "Prior Therapy",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Adjuvant Hormonal Therapy",
      "group_data": [
        {
          "group_name": "Palbociclib-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.7,
          "raw_string": "3 (0.7)"
        },
        {
          "group_name": "Placebo-Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.8,
          "raw_string": "4 (1.8)"
        }
      ]
    }
  ]
}